Yang, J., Chaudhry, B. I., Yue, A. T., Roth, J. A., Kelton, J. M., Shelbaya, A., Tran, L., & Li, M. (2023). The Impact of Biosimilar Use on Total Cost of Care and Provider Financial Performance in the Medicare Oncology Care Model: A Population-Based Simulation Study. Advances in Therapy, 41(1), 349–363. https://doi.org/10.1007/s12325-023-02703-x

Smolen, J. S., Landewé, R. B. M., Bergstra, S. A., Kerschbaumer, A., Sepriano, A., Aletaha, D., Caporali, R., Edwards, C. J., Hyrich, K. L., Pope, J. E., de Souza, S., Stamm, T. A., Takeuchi, T., Verschueren, P., Winthrop, K. L., Balsa, A., Bathon, J. M., Buch, M. H., Burmester, G. R., … van der Heijde, D. (2022). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the Rheumatic Diseases, 82(1), 3–18. https://doi.org/10.1136/ard-2022-223356

Abraham, B., Eksteen, B., Nedd, K., Kale, H., Patel, D., Stephens, J., Shelbaya, A., Chambers, R., & Soonasra, A. (2022). Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study). Advances in Therapy, 39(5), 2109–2127. https://doi.org/10.1007/s12325-022-02104-6